US Patent Issued to BEIJING JIYUAN BIOLOGICAL TECHNOLOGY on Sept. 16 for "Method of treating diabetes with FGF21 and GLP1 double gene-modified cell" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 17 -- United States Patent no. 12,414,966, issued on Sept. 16, was assigned to BEIJING JIYUAN BIOLOGICAL TECHNOLOGY Co. LTD. (Beijing).

"Method of treating diabetes with FGF21 and GLP1 double gene-modified cell" was invented by Haifeng Duan (Beijing), Binghua Xue (Beijing), Jing Xie (Beijing) and Zhenli Zhang (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a modified mesenchymal stem cell and culture supernatant thereof, and a pharmaceutical composition comprising said cell or culture supernatant thereof. The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising t...